Multiple Myeloma
The Polish Myeloma Consortium supports clinical research in multiple myeloma with a focus on treatment strategies for patients with biochemical relapse and newly diagnosed disease. Its research activity includes evaluation of anti-CD38 therapy and combination regimens used in disease control.
- Daratumumab-based therapy
- Relapsed myeloma
- Newly diagnosed multiple myeloma
- Combination treatment regimens
Clinical interest extends to outcomes linked with disease progression, response maintenance, and prevention of symptomatic relapse in plasma cell dyscrasias.
Minimal Residual Disease
Research activity also centers on minimal residual disease in multiple myeloma, with attention to patients in whom residual disease reappears after prior response. The sponsor’s trials examine treatment approaches aimed at restoring disease control when MRD positivity returns.
- MRD reappearance
- MRD-negative complete response
- Response durability
- Event-free survival
This area reflects a strong therapeutic interest in deep response states and the clinical significance of residual disease monitoring in hematologic malignancy care.
Relapse Prevention and Disease Control
The sponsor’s portfolio includes studies addressing early intervention after signs of relapse, particularly in patients showing biochemical relapse or renewed MRD. These investigations focus on delaying symptomatic progression and preserving remission in myeloma.
- Preventive therapy
- Biochemical relapse
- Symptomatic progression
- Progression-free survival
The therapeutic emphasis is on maintaining disease stability and limiting transition to CRAB features associated with worsening clinical status.
